Detection of Anti-Platelet Factor 4 Antibodies in Acute and Chronic Thromboembolic Disease—A Pilot Study
International Journal of Molecular Sciences · 05.11.2026 · 27 (21) · 9899
DOI: 10.3390/ijms27219899 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2026. Verfasst von Annabell Trunk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Coagulation Centre, Cardiology Angiology Centre Bethanien Hospital (CCB), 60389 Frankfurt, Germany. Hauptthemen laut MEDLINE: Platelet Factor 4, Thromboembolism, Autoantibodies. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Heterogeneous antibodies directed against platelet factor 4 (PF4-Abs) are associated with heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT). Emerging evidence suggests that these antibodies may also occur in other thromboembolic diseases. In this pilot study, we assessed the prevalence of PF4-Abs in patients with acute thromboembolism and in patients with thromboembolic antiphospholipid syndrome (APS), a chronic autoimmune thrombophilia. Forty patients with acute thromboembolism and 43 patients with APS were included. Both heparin-dependent and heparin-independent PF4-Abs were evaluated using multiple assay platforms, including a prototype chemiluminescence assay for heparin-independent PF4-Abs, an anti-PF4/polyanion IgG chemiluminescence assay, a latex agglutination assay detecting anti-PF4/polyanion IgG/IgM/IgA antibodies, an anti-PF4/heparin IgG ELISA, and functional platelet activation tests. Across the different assays, positivity in at least one assay was observed in 27.5% (11/40) of patients with acute thromboembolism and 27.9% (12/43) of patients with APS. In most antibody-positive patients, no recent heparin exposure was documented. Functional platelet activation was predominantly absent, arguing against a classical HIT- or VITT-like mechanism. Overall, these results demonstrate assay-dependent PF4-Ab positivity in a substantial proportion of patients with acute and chronic thromboembolic conditions. Their clinical and pathogenic relevance remains unclear and warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Coagulation Centre, Cardiology Angiology Centre Bethanien Hospital (CCB), 60389 Frankfurt, Germany.
- Coagulation Research Centre Bethanien Hospital, 60389 Frankfurt, Germany.
- Institute for Transfusion Medicine, University Hospital Greifswald, 17475 Greifswald, Germany.
- Werfen, 08186 Lliçà d'Amunt, Barcelona, Spain.
- Goethe University Frankfurt, Institute of Biostatistics and Mathemical Modelling, 60590 Frankfurt, Germany.
ORCID-Profile: Jan Wesche, Marina Bruch-Oms, Eva Herrmann, Thomas Thiele, Edelgard Lindhoff-Last
Zitieren
APA
Trunk, A., Wesche, J., Jacobi, S., Bruch-Oms, M., Metzler, D., Herrmann, E., Thiele, T., & Lindhoff-Last, E. (2026). Detection of Anti-Platelet Factor 4 Antibodies in Acute and Chronic Thromboembolic Disease—A Pilot Study. International Journal of Molecular Sciences, 27(21), 9899. https://doi.org/10.3390/ijms27219899
Vancouver
Trunk A, Wesche J, Jacobi S, Bruch-Oms M, Metzler D, Herrmann E, et al. Detection of Anti-Platelet Factor 4 Antibodies in Acute and Chronic Thromboembolic Disease—A Pilot Study. International Journal of Molecular Sciences. 2026;27(21):9899. doi:10.3390/ijms27219899
BibTeX
@article{Trunk2026,
author = {Trunk, Annabell and Wesche, Jan and Jacobi, Stella and Bruch-Oms, Marina and Metzler, Donata and Herrmann, Eva and Thiele, Thomas and Lindhoff-Last, Edelgard},
title = {Detection of Anti-Platelet Factor 4 Antibodies in Acute and Chronic Thromboembolic Disease—A Pilot Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9899},
doi = {10.3390/ijms27219899}
}
EUVIMED